TCGA-CN-4730-01A-01R-1436-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.640
- MYC_TARGETS_V2+0.620
- OXIDATIVE_PHOSPHORYLATION+0.500
- E2F_TARGETS+0.490
- G2M_CHECKPOINT+0.430
- MTORC1_SIGNALING+0.390
- PANCREAS_BETA_CELLS+0.370
- DNA_REPAIR+0.290
- FATTY_ACID_METABOLISM+0.240
- SPERMATOGENESIS+0.210
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.410
- ALLOGRAFT_REJECTION-0.370
- NOTCH_SIGNALING-0.370
- WNT_BETA_CATENIN_SIGNALING-0.350
- IL6_JAK_STAT3_SIGNALING-0.340
- TNFA_SIGNALING_VIA_NFKB-0.340
- INFLAMMATORY_RESPONSE-0.330
- APICAL_SURFACE-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.290
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-AR-A0TY-01A-12R-A115-07 | — | B | 0.925 |
| 2 | TCGA-66-2754-01A-01R-0980-07 | — | cohortA3 | 0.898 |
| 3 | 4e2a5058-c190-49de-97f4-0ba7be7ebfe8 | — | — | 0.893 |
| 4 | ec51dd1b-5733-485c-a09a-8d50d1d9fda1 | — | — | 0.886 |
| 5 | TCGA-DQ-7588-01A-11R-2081-07 | — | — | 0.882 |
| 6 | TCGA-33-4582-01A-01R-1443-07 | — | cohortSQ2 | 0.880 |
| 7 | SRR8518383 | — | E | 0.874 |
| 8 | MNG1063 | — | — | 0.871 |
| 9 | AUR-AFUM-TTM1-A-1-1-R-A743-41 | — | E | 0.870 |
| 10 | debb199a-24be-4e87-84ea-2df67673457a | — | — | 0.867 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.640 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.620 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.500 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.490 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.430 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.370 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.290 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.240 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.210 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.210 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.200 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.190 | Idelalisib | — uncovered |
| PEROXISOME | 0.190 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.170 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.150 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.080 | Temsirolimus | — uncovered |
| BILE_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |